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We assessed patients’ health-related quality of life after myocardial infarction
and identified related variables.  Clinical data were obtained retrospectively
from medical records of consecutive patients admitted to a Midwestern
university-affiliated medical center with diagnosis of myocardial infarction
from July 1999–July 2000.  Telephone interviews 7 months after discharge
were made to administer the Short Form-12 (SF-12) and obtain patient,
disease, drug, and intervention data.  Complete information was obtained
from 200 patients (mean age 63.4 ± 13.1 yrs, 68% men).  The mean Physical
Component Summary (PCS)-12 score was 40.6 ± 12.0, and the mean Mental
Component Summary (MCS)-12 score was 52.1 ± 10.0.  Based on univariate
analyses, low PCS-12 scores were associated with women; non–Q-wave
infarctions; greater number of illnesses; history of myocardial infarction,
chronic heart failure (CHF), transient ischemic attack (TIA), renal disease,
peripheral vascular disease, or percutaneous coronary intervention (PCI);
rehospitalization during the interim period; and unscheduled PCI since index
myocardial infarction.  Low MCS-12 scores were associated with age below 65
years, low overall self-reported drug therapy compliance, low self-reported
compliance with angiotensin-converting enzyme inhibitor and lipid-lowering
therapy, no history of coronary artery bypass graft, and no stress test since
index myocardial infarction.  A multivariate regression model for PCS-12 kept
the following variables:  greater number of illnesses, history of CHF or TIA,
and rehospitalization since index myocardial  infarction.  The MCS-12 model
contained age below 65 years, low overall compliance, and low compliance
with lipid-lowering therapy.  Further work is necessary to determine
noncardiovascular predictors of quality of life and whether interventions for
these patients will result in improved quality of life.
(Pharmacotherapy 2002;22(12):1616–1622)
After a myocardial infarction, patients often
experience physical and emotional effects related
to the event that impair functioning to the point
of interfering with housework, work for pay,
social life, and other important activities.  They
may experience anxiety and depression that were
not present before the event, which may
exacerbate existing conditions.1–3 General and
disease-specific instruments may capture patient-
reported outcomes such as health-related quality
of life (HRQOL).  Health-related quality of life
complements physiologic and clinical markers of
cardiovascular disease and/or its treatment, and
has been studied in patients with myocardial
infarction.4–17 Many of these were controlled
clinical trials assessing the effectiveness of an
intervention.  Such studies provide a way to
move from measuring outcomes to improving
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care for groups and individual patients.
When studying population-based HRQOL,
patient, disease, treatment, and health care
delivery system are all possible influences.  In
patients who experienced a recent myocardial
infarction, these variables may include demo-
graphics, severity of illness, revascularization
procedures, drug therapy, and comorbidity.  For
example, cardiac as well as noncardiac problems
were associated with the two summary measures
of the Short Form (SF)-36, a general HRQOL
instrument, in a predominantly male population
7 months after discharge for acute coronary
syndrome.6 The SF-12, a shorter version of the
SF-36, was mailed to patients who had had a
myocardial infarction 2 years earlier and revealed
that chest pain and a history of smoking at the
time of infarction were associated with low
HRQOL.5
Data pertaining to cardiac care before, during,
and after hospitalization for myocardial
infarction, together with patient and provider
characteristics, are often available for quality-
assurance programs.  The addition of patient-
reported outcomes such as HRQOL broaden the
scope of assessment of care.  We evaluated the
relationship between HRQOL and common
patient, disease, and treatment-intervention
variables 7 months after discharge for treatment
of acute myocardial infarction.
Methods
This was a cross-sectional study of patients
aged 18 years and older with the primary or
secondary discharge diagnosis of acute myo-
cardial infarction (International Classification of
Diseases [ICD]-9 code 410) between July 1,
1999, and July 31, 2000.  Those who were alive
at the time of the follow-up interview constituted
the study sample.  They had to understand and
be able to communicate in English so as to
participate in the telephone survey.  There were
no other exclusion criteria.  Patient demographic
and selected cardiac history data were used for a
nonresponse bias assessment of potential
respondents who were assumed to be alive but
whom investigators were unable to contact.  The
study was approved by the human investigations
committee of the affiliated medical school.
Data Collection
A cardiology nurse clinician and two cardiac
medicine fellows obtained information regarding
patient demographics, medical history, and
hospital course by reviewing medical records.
This information was entered into a database that
is used for quality-assurance projects and reports.
An investigator contacted patients at home by
telephone approximately 6–7 months after
discharge and administered the survey.  At least
five attempts during different times of the day
were made to contact patients.
Patient and Disease Characteristics
Patient and disease characteristics were
obtained by both chart review and patient self-
reports during telephone interviews.  Age, sex,
race, marital status, number of other documented
illnesses, type of myocardial infarction, ejection
fraction at the time of discharge or shortly
afterward, and drugs prescribed at discharge were
obtained from medical records.  Body mass index
(BMI) was calculated from recorded height and
weight.
Treatment Characteristics
Medical history before admission was obtained
from records and included diagnoses and cardiac-
related procedures.  Procedures included
occurrence at any time of coronary artery bypass
surgery (CABG), percutaneous transluminal
coronary angioplasty (PTCA) or percutaneous
coronary intervention (PCI), or cardiac
catheterization.  The same information was
obtained from medical records of hospitalization
for the index myocardial infarction.  Events and
procedures that occurred between discharge and
telephone survey were recorded during telephone
interviews; for example, rehospitalization for
cardiac problems, occurrence of stroke,
scheduled and unscheduled revascularization
procedures (e.g., PCI, CABG), scheduled or
unscheduled cardiac catheterization, and exercise
stress tests.
A drug list was constructed during interviews
as reported by patients.  Agents relevant to this
analysis were antiplatelet and/or anticoagulant
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drugs, b-blockers, angiotensin-converting
enzyme (ACE) inhibitors (or angiotensin II
receptor blockers), and lipid-lowering drugs.
Self-reported compliance with therapy was
assessed by a 4-item scale.18
Health-Related Quality of Life
Health-related quality of life was measured
with the SF-12, a generic measure of health
status for use in population surveys.19 It includes
one or two items from each of the eight health
concepts measured by the SF-36 and contains
two summary measures of functioning and well-
being:  Physical Component Summary (PCS-12)
and Mental Component Summary (MCS-12);
these provide the same information as the SF-36
summary measures.  Item scores are coded,
summed, and transformed to a scale ranging
from 0 (worst health status) to 100 (best health
status), and adjusted to norm-based scaling for a
final score for each health concept.  The
questionnaire uses a 4-week recall period.
Data Analyses
Summary statistics were presented as
frequencies and percentages or as means,
medians, and SD.  Univariate associations
between HRQOL scores (PCS-12, MCS-12) and
nominal explanatory variables were examined
with the Wilcoxon rank sum test.  Age, BMI, and
number of other illnesses were recoded as
univariate variables based on the median split of
variable data.  Ejection fraction data were split at
40%.
Multivariate linear regression was conducted to
determine the strength of association between
patient and disease characteristics and the PCS-
12 and MCS-12 scores.  Spearman’s correlation
was performed to identify highly related
explanatory variables.  If the R value was greater
than 0.4, the pair of variables and correlation
pattern with other variables were examined and a
decision was made to leave or remove it from the
regression model.  Variables “history of
catheterization before the reference myocardial
infarction” and “occurrence of catheterization
during the interim period (between discharge
and survey)” were removed due to high
correlation with a number of other explanatory
variables.
Two groups of explanatory variables were
created.  The first group consisted of patient
demographics, prehospitalization history and
procedures, and hospitalization-related data.  The
second group entered into the regression model
consisted of events that occurred between
discharge for the reference myocardial infarction
and time of the survey.  Noncontributory
explanatory variables were eliminated from the
model using backward stepwise elimination of
variables with a p value greater than 0.1.  The
final regression models were developed by
stepwise backward elimination with inclusion
variables having a p value of 0.05 or less.  A p
value of 0.05 was chosen to develop a
parsimonious set of predictor variables for the
final models.  Two separate models were
developed, one for each dependent variable, PCS-
12 and MCS-12.  SAS (SAS Institute, Cary, NC)
was used for analyses.
Results
During the study period 258 patients were
discharged from the hospital.  Of these, 26
patients (10%) were lost to follow-up or died,
and 32 (12%) had incomplete information for
analysis, leaving 200 (78%) as the sample (Table
1).  Nonresponse bias assessment showed that
more nonrespondents than respondents had a
history of transient ischemic attack (TIA),
diabetes, renal insufficiency, peripheral vascular
disease, CABG, and previous myocardial
infarction.
Mean follow-up was 7.3 ± 1.5 months.  Almost
all patients had at least one comorbidity at the
time of the index myocardial infarction.  Most
common were angina, smoking, hyperlipidemia,
and hypertension.  Many patients (32.5%) had a
history of myocardial infarction.  Over two thirds
had an ejection fraction of 40% or greater at the
time of or immediately after discharge for the
index myocardial infarction.  Revascularization
procedures were performed during hospital-
ization or during the interim (discharge to
survey) in 71% of patients.  The mean PCS-12
score was 40.6, and mean MCS-12 score was
52.1.
Table 2 shows results of univariate analyses
that were statistically significant.  Significant
differences in PCS-12 scores were observed based
on sex, type of myocardial infarction, number of
other illnesses, history of myocardial infarction,
history of chronic heart failure (CHF), history of
TIA, history of renal disease, history of peripheral
vascular disease, history of PCI, rehospitalization
for heart disease since index myocardial
infarction, and unscheduled PCI since index
infarction.  Significant differences in MCS-12
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scores were seen based on age, history of CABG,
self-reported drug therapy compliance, and two
drugs, lipid-lowering agents and ACE inhibitors.
Regression analysis for the PCS-12 model is
presented in Table 3.  The final PCS-12 model
had an adjusted R2 of 0.21 and model coefficient
of 0.48.  Explanatory variables included in the
final PCS-12 model were number of comorbidities,
rehospitalization due to heart disease during the
interim period, and history of CHF, TIA, and PCI
before the index myocardial infarction.  Histories
of CHF, TIA, and PCI (which indicates existing
coronary artery disease) were similarly influential,
and when present before the index myocardial
infarction were related to lower PCS-12 scores.
Also related to lower PCS-12 scores were greater
number of other illnesses and hospitalization
since discharge for the index infarction.
Table 4 shows regression analysis for the MCS-
12.  The MCS-12 regression model had an
adjusted R2 of 0.13 and a regression model
coefficient of 0.38.  Three explanatory variables
were included in the final model:  age, self-
reported compliance, and lipid-lowering therapy.
Older age, greater compliance, and need for lipid-
lowering therapy were associated with higher
MCS-12 scores.
Discussion
Goals of therapy for patients after myocardial
infarction are generally to alleviate symptoms,
improve functional abilities, and slow or halt
disease progression.  The HRQOL provides
information pertaining to the effect of the event
and/or intervention on the patient’s life.  Our
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Table 1.  Characteristics of Respondents
Variable No. (%) of Patients
Age (yrs), mean ± SD 63.4 ± 13.1
Median 63.6
Range 32–92
Race
Caucasian 169 (84.5)
Other or unknown 31 (15.5)
Marital status
Married 137 (68.5)
Not married 63 (31.5)
Men 136 (68.0)
No. of other documented diagnoses
0 12 (6.0)
1 52 (26.0)
2 73 (36.5)
3 38 (19.0)
‡ 4 25 (12.5)
Body mass index (m2), mean ± SD 28.4 ± 6.3
Median 27.2
Range 16.0–63.5
Diagnoses and procedures before index
myocardial infarction
Angina 122 (61.0)
Smoking 125 (62.5)
Myocardial infarction 65 (32.5)
Chronic heart failure 24 (12.0)
Transient ischemic attacks 18 (9.0)
Diabetes mellitus 36 (18.0)
Malignancy 20 (10.0)
Renal disease 21 (10.5)
Positive stress test 22 (11.0)
Peripheral vascular disease 31 (15.5)
Hypertension 122 (61.0)
Hyperlipidemia 106 (53.0)
Atrial fibrillation 22 (11.0)
Percutaneous coronary intervention 33 (16.5)
Coronary artery bypass graft surgery 30 (15.0)
Variables during hospitalization
Type of myocardial infarction
Q-wave 63 (32.5)
Non–Q-wave 131 (67.5)
Ejection fraction at discharge or
shortly thereafter
< 40% 62 (31.0)
‡ 40% 138 (69.0)
Percutaneous coronary intervention
during hospitalization 114 (57.0)
Coronary artery bypass graft surgery
during hospitalization 18 (9.0)
Variables at the time of the survey
Cardiovascular-related drugs
Aspirin and/or other antiplatelet agents 171 (85.5)
b-Blockers 87 (43.5)
Angiotensin-converting enzyme
inhibitors 116 (58.0)
Calcium channel blockers 22 (11.0)
Statin and/or other lipid-lowering agents 145 (72.5)
Self-reported drug compliance score
Noncompliant 72 (37.1)
PCS-12 score, mean ± SD 40.6 ± 12.0
Median 41.5
Range 16.7–62.2
Table 1.  Characteristics of Respondents (continued)
Variable No. (%) of Patients
MCS-12 score, mean ± SD 51.1 ± 10.0
Median 55.3
Range 24.1–68.8
Events between discharge after index
myocardial infarction and survey
Rehospitalization for cardiac problem 60 (28.2)
Stroke 3 (1.4)
Scheduled percutaneous coronary
intervention 16 (7.6)
Scheduled coronary artery bypass graft 8 (3.8)
Unscheduled percutaneous coronary
intervention 8 (3.8)
Unscheduled coronary artery bypass graft 1 (0.5)
Myocardial infarction 13 (10.0)
Stress test 44 (24.7)
PCS = Physical Component Summary; MCS = Mental Component
Summary.
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study provides some insight into the efficacy of
the SF-12 as a general measure of HRQOL in this
population.
A number of predictor variables, primarily
cardiac related, were associated with the PCS-12;
these variables were obtained from a quality-
assurance database used to monitor the care of
patients in the health system.  The relationship
between a history of PCI and the index
myocardial infarction may indicate severe heart
disease and may have led to the lower physical
HRQOL summary score.  The lack of effect of
revascularization procedures either during
hospitalization or during the period between
hospital discharge and the survey was somewhat
unexpected.  Other controlled trials found that
revascularization procedures improve HRQOL.14,
20–24 However, one group reported findings
similar to ours, with need for revascularization
being related to impaired HRQOL.4 Most often,
study questionnaires were administered at the
time of PCI and at some point after the
procedure.  This was different from our study, in
which having had a PCI during hospitalization or
interim period most likely represented a more
severely ill patient.
A history of CHF or TIA before the index
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Table 2.  Univariate Analyses of Patient and Disease
Characteristics and PCS-12 and MCS-12 Scoresa
Variable PCS-12 Score MCS-12 Score
Age (yrs) NS p=0.006
≤ 63.4 yrs 41.4 ± 12.9 50.0 ± 10.7
‡ 63.5 39.9 ± 11.0 54.1 ± 8.8
Sex p=0.02 NS
Men 42.0 ± 12.3 52.1 ± 9.8
Women 37.8 ± 11.0 52.0 ± 10.4
Type of MI p=0.04 NS
Q wave 43.2 ± 11.8 52.8 ± 9.2
Non–Q wave 39.7 ± 12.1 51.5 ± 10.4
No. of other illnesses p=0.006 NS
≤ 2 42.2 ± 11.9 51.6 ± 10.1
‡ 3 37.2 ± 11.6 53.2 ± 9.7
Self-reported drug
compliance NS p=0.001
Not compliant 40.0 ± 12.3 49.8 ± 10.5
Compliant 40.7 ± 11.8 53.6 ± 9.5
History of MI p=0.002 NS
Yes 36.8 ± 11.5 52.7 ± 9.7
No 42.5 ± 11.8 51.8 ± 10.1
History of TIA p=0.001 NS
Yes 31.2 ± 8.8 49.9 ± 10.2
No 41.6 ± 11.9 52.3 ± 10.0
History of renal disease p=0.003 NS
Yes 33.3 ± 10.2 50.6 ± 8.9
No 41.5 ± 11.9 52.3 ± 10.1
History of PVD p=0.02 NS
Yes 34.3 ± 10.9 53.2 ± 9.7
No 41.8 ± 11.9 51.9 ± 10.0
History of PCI p=0.004 NS
Yes 35.2 ± 10.3 54.4 ± 9.6
No 41.7 ± 12.0 51.6 ± 10.0
History of CABG NS p=0.001
Yes 36.6 ± 12.1 55.8 ± 8.2
No 41.3 ± 11.9 51.4 ± 10.1
Rehospitalized for heart
disease since index MI p<0.001 NS
Yes 35.4 ± 10.9 51.7 ± 10.4
No 42.1 ± 11.7 52.4 ± 9.9
Unscheduled PCI since MI p=0.03 NS
Yes 31.3 ± 13.2 50.5 ± 12.2
No 40.7 ± 11.6 52.3 ± 10.0
Stress test since MI NS p=0.006
Yes 42.0 ± 11.4 55.4 ± 8.1
No 40.3 ± 11.9 49.3 ± 11.3
Prescribed ACE inhibitors NS p=0.02
Yes 41.3 ± 11.4 53.2 ± 10.3
No 39.7 ± 12.8 50.5 ± 9.4
Prescribed lipid-lowering
agents NS p=0.04
Yes 41.2 ± 12.1 53.3 ± 9.3
No 39.6 ± 11.9 49.8 ± 10.7
PCS = Physical Component Summary; MCS = Mental Component
Summary; NS = not significant; MI = myocardial infarction; TIA =
transient ischemic attack; PVD = peripheral vascular disease; PCI =
percutaneous coronary intervention; CABG = coronary artery
bypass graft; ACE = angiotensin-converting enzyme.
The table includes only statistically significant comparisons.
aData are mean ± SD.
Table 3.  Final Multivariate Linear Regression Model for
PCS-12 Scores
Standard
Regression Regression
Variable Coefficient Coefficient p Value
History of CHF -5.7 -0.16 0.02
History of TIA -5.7 -0.14 0.04
History of PCI -4.7 -0.15 0.02
Total no. of other
illnesses -2.4 -0.24 0.001
Rehospitalization due
to heart disease -6.3 -0.24 <0.001
PCS = Physical Component Summary; CHF = chronic heart failure;
TIA = transient ischemic attack; PCI = percutaneous coronary
intervention.
Table 4.  Final Multivariate Linear Regression Model for
MCS-12 Scores
Standard
Regression Regression
Variable Coefficient Coefficient p Value
Age 0.17 0.22 0.001
Compliance dichotomized 6.60 0.24 0.001
Lipid-lowering therapy 4.3 0.20 0.003
MCS = Mental Component Summary.
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myocardial infarction was associated with lower
PCS-12 scores.  In fact, CHF was a major variable
in one risk model,6 and the presence of TIA is
known to be associated with reduced physical
functioning.25 Being rehospitalized after the
index myocardial infarction also had a negative
association with the PCS-12 score, findings
similar to another study in which subsequent
stroke or reinfarction greatly impaired HRQOL.26
All three variables (CHF, TIA, rehospitalization
due to cardiac reasons) indicate continuing
cardiac and/or vascular illness and may represent
advanced disease.
Women in this study had lower PCS-12 scores
than men on univariate analysis, as reported in
other studies of HRQOL after myocardial
infarction.13, 15, 27 However, in our study, sex was
eliminated from both PCS-12 and MCS-12
regression models, indicating a weaker relation-
ship than the remaining variables.
Comorbidities had a negative association with
PCS-12 scores.  Simply having more comor-
bidities tends to lower HRQOL in all dimensions
measured in patients with cardiac disease.13 A
survey in a general population in a health district
in Sweden found a negative association between
number of chronic diseases and HRQOL.28 The
impact was reduced slightly when adjusted for
age but was still substantial.  Thus researchers
using general instruments such as the SF-12
must be aware of this effect.
The mental health domain was associated with
age, with older age related to better mental health
summary scores.  This relationship was documented
in SF-12 development as well as in independent
assessments using respondents drawn from
population studies and patients who experienced
a recent myocardial infarction.13 Self-reported
drug therapy compliance had a positive
association with the mental health domain, in
that patients with fewer depression-anxiety
symptoms, as measured by MCS-12, had higher
self-reported compliance.  The negative relation-
ship between depression and noncompliance is
well documented.29 Depression after myocardial
infarction that negatively affects HRQOL was
reported in a number of studies1–3 and may be
linked to increased morbidity and mortality.30, 31
These patients should be monitored closely for
drug compliance.
Of the four cardiac drugs examined in this
study, only lipid-lowering agents were associated
with an HRQOL measure in the regression
models.  Patients who had lower MCS-12 scores,
indicating depressive and/or anxiety-related
effects, were most likely to report that they were
not taking these drugs, even when they were
prescribed at discharge.  Drug treatment for a
relatively asymptomatic condition, elevated
cholesterol, may be associated with lower
compliance rates than other treatments for more
symptomatic conditions such as ischemia after
myocardial infarction.  We did not assess patients
for depression or anxiety using specific screening
or diagnostic instruments, which may explain the
limited amount of variance explained by the
predictor variables in the final mental health
regression model.  In other studies depression
was a significant predictor of HRQOL.6
Identification and treatment of depression or
depressive symptoms may improve compliance
and improve long-term benefits of treatment.
The ejection fraction did not have an
association with either PCS-12 or MCS-12 scores.
This is the same result as in another study,6
although one group reported a relationship
between left ventricular ejection fraction and
HRQOL, with lower ejection fraction predictive
of lower HRQOL.13 One potential limitation in
our study is that the ejection fraction was
measured during or immediately after discharge
from the hospital for the index myocardial
infarction, whereas the questionnaire was
administered approximately 7 months later.
Thus changes in ejection fraction may have
occurred that were not measured by the survey.
Future studies to develop and validate self-
reported measures of cardiac function would be
useful when it is difficult to obtain objective data
such as ejection fraction.
This study had several potential limitations.
We included only one measure of HRQOL at
approximately 7 months after myocardial
infarction.  Serial measures of HRQOL may have
been able to detect changes that occurred
immediately after discharge as well as 1 year and
longer after the event.  The fact that a baseline
assessment was not performed allows only for an
association rather than causality.  Also not
measured were symptoms related to ischemic
heart disease and CHF.  Similarly, patient
perceptions of illness and disease severity, as well
as noncardiovascular events, were not measured,
and these variables may modify or influence
patients’ perception of change in functioning or
HRQOL.
Conclusion
Health-related quality of life scores were low 7
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months after myocardial infarction.  Physical
scores (PCS-12) were especially lower for
patients with more concomitant diseases; history
of PCI, CHF, or TIA; and rehospitalization in the
interim period.  Mental scores (MCS-12) were
significantly lower for those younger than 65
years and those reporting lower overall
compliance with drug therapy, lipid-lowering
therapy in particular.  After a patient has a
myocardial infarction, particular attention should
be paid to the patient’s cardiovascular medical
history.  Further work is necessary to determine
noncardiovascular predictors of quality of life
and whether interventions aimed at these
patients will result in improved quality of life.
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